Equities analysts expect Wave Life Sciences Ltd (NASDAQ: WVE) to record revenues of $ 6.04 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for the profits of Wave Life Sciences, with estimates ranging from $ 700,000.00 to $ 14.40 million. Wave Life Sciences posted sales of $ 680,000.00 in the same quarter last year, indicating positive year-on-year growth of 788.2%. The company will report on its earnings figures for the next quarter on Thursday, November 8.
On average, analysts expect Wave Life Sciences to report annual sales of $ 23.65 million for the current fiscal year, with estimates ranging from $ 6.50 million to $ 44.50 million. For the next financial year, analysts expect the company to record sales of $ 49.13 million per share, with estimates ranging from $ 5.16 million to $ 121.00 million. The sales calculations of Zacks Investment Research are an average average based on a survey among research firms that offer cover for Wave Life Sciences.
Wave Life Sciences (NASDAQ: WVE) last announced its earnings on Thursday 9 August. The company reported ($ 1.23) earnings per share (EPS) for the quarter, with consensus estimates of ($ 0.35) analysts being missed ($ 0.88). The company had sales of $ 4.88 million during the quarter compared with analyst estimates of $ 7.38 million. Wave Life Sciences had a negative net margin of 2,613.03% and a negative return on equity of 76.93%.
A number of analysts have put the company under heavy pressure. ValuEngine increased Wave Life Sciences from a & # 39; hold & # 39; -rating to a & # 39; buy & # 39; rating in a research report on Saturday 2 June. TheStreet cut Wave Life Sciences from a "c" rating to a "d +" rating in a report on Thursday, May 31. BidaskClub increased Wave Life Sciences from a "buy" rating to a "strong buy" rating in a report on Thursday 7 June. Stifel Nicolaus started in a report on Monday about Wave Life Sciences. They gave a "buy" rating and a $ 56.00 price target for the company. In the end, Mizuho set a target price of $ 65.00 on Wave Life Sciences and gave the company a & # 39; buy & # 39; credit rating in a report on Thursday. One analyst has rated the shares with a sell rating, six have been awarded a buy-rating and two have a strong buy-rating assigned to the company's shares. Wave Life Sciences currently has an average rating of "Buy" and a target price target of $ 55.33.
In other Wave Life Sciences news, insider Chris Francis sold 24,496 shares of the share in a transaction on Monday 9 July. The stock was sold at an average price of $ 37.27 for a total transaction of $ 912,965.92. The transaction was announced in an application to the Securities & Exchange Commission, which is accessible via this hyperlink. Insider Paul Bolno also sold 31,711 shares of the company's shares in a transaction on Wednesday 30 May. The stock was sold at an average price of $ 45.00, for a total value of $ 1,426,995.00. The information for this sale can be found here. Insiders have sold 105,199 shares of the company's shares in the last three months, valued at $ 4,630,337. 44.20% of the stock is currently owned by company insiders.
A number of institutional investors have recently increased or reduced their interests in the company. Zurcher Kantonalbank Zurich In the first quarter, Cantonalbank acquired a new shareholding in Wave Life Sciences worth $ 120,000. California Public Employees Retirement System acquired a new shareholding in Wave Life Sciences worth $ 219,000 in the first quarter. Goldman Sachs Group Inc. acquired a new shareholding in Wave Life Sciences worth $ 222,000 in the fourth quarter. Millennium Management LLC acquired a new shareholding in Wave Life Sciences worth $ 330,000 in the first quarter. Finally, in the second quarter, the State Board of Administration of Florida Retirement System acquired a new shareholding in Wave Life Sciences worth $ 334,000. 80.78% of the shares are held by institutional investors.
Wave Life Sciences traded $ 0.25 and reached $ 39.25 during midday trading on Tuesday, reports Marketbeat. 400 shares of the company were traded, compared with the average volume of 139,522. Wave Life Sciences has a twelve month low of $ 16.05 and a twelve month high of $ 55.95. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.04. The shares have a market capitalization of $ 1.17 billion, a price-earnings ratio of -10.25 and a beta of 0.69.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a biotechnology company, designs, develops and commercialises therapeutic nucleic acid candidates for genetically determined diseases by using their own development platform for synthetic chemistry. The company mainly develops oligonucleotides that target genetic defects to reduce the expression of pathogenic proteins or to transform the production of dysfunctional mutant proteins in the production of functional proteins.
Read more: market capitalization – what it means for investors
Receive a free copy of the Zacks research report on Wave Life Sciences (WVE)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive daily news and valuations for Wave Life Sciences – Please provide your email address below for a concise, daily summary of the latest news and reviews from analysts for Wave Life Sciences and related companies with the FREE daily email newsletter from MarketBeat.com.